CLL Coverage from Every Angle

Jeff P. Sharman, MD, on Clinical Pearls on Treatments Containing Acalabrutinib

Posted: Wednesday, December 11, 2019

Jeff P. Sharman, MD, of the Willamette Valley Cancer Institute and US Oncology Research, talks about the most significant clinical issues that practitioners need to be aware of when patients are receiving a regimen containing acalabrutinib.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.